Regeneron Pharmaceuticals Inc. (REGN) announced detailed analyses from the Phase 3 C-POST trial, which evaluated PD-1 inhibitor Libtayo (cemiplimab)in patients with high-risk cutaneous squamous cell carcinoma after surgery.
The results include additional data for the primary endpoint of disease-free survival (DFS) and the first presentation of key secondary endpoint outcomes.
The Phase 3 C-POST trial demonstrates that cemiplimab is a highly active therapy in high-risk cutaneous squamous cell carcinoma, with clinically meaningful outcomes across primary and secondary endpoints and exceptionally low rates of locoregional and distant recurrence.
The company noted that Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial. Libtayo also demonstrated 80% and 65% reductions in the risk of locoregional and distant recurrence, respectively, compared to placebo.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.